The regulatory picture is split. The FDA and the American Heart Association have warned against using unapproved cuffless devices for clinical decisions. The AHA's scientific statement, published online in December 2025, says FDA clearance does not establish real-world accuracy because no formal clinical validation protocol is required. The 2025 AHA/ACC hypertension guideline rates cuffless devices Class 3: No Benefit for diagnosing or managing hypertension. Most wearables from Oura, Fitbit and Garmin remain sold as wellness features, not cleared measurement tools. Whether the Happy Health clearance will change how clinicians view cuffless monitoring is not yet settled. Doctors have not yet built a consensus on the evidence needed to justify clinical use.
For attorneys, the practical questions are about labeling and expectations. Check whether a client's device is cleared for measurement or marketed only for wellness, because that distinction determines what the company can claim. Watch for patients who rely on a ring or band reading in place of a cuff, and for cases where a device flags a shift the user cannot feel. High blood pressure often produces no symptoms, so an alert can prompt needed care or cause anxiety without clinical meaning. A 2025 JAMA Cardiology paper from an international panel argued that consumer estimates cannot be checked against the cuff standard, which is likely to shape how plaintiffs and defendants frame accuracy disputes.